Jason E Bonner1, Denise A Esserman, Carol E Golin, Donna M Evon. 1. Departments of *Medicine, Division of Gastroenterology and Hepatology †Medicine ‡Biostatistics, Gillings School of Public Health §Division of General Medicine and Clinical Epidemiology, University of North Carolina, Chapel Hill, NC.
Abstract
GOALS: To investigate the role of self-efficacy (SE) during hepatitis C virus (HCV) treatment. BACKGROUND: Adherence to chronic HCV treatment is critical. SE is an important predictor of medication adherence in a number of chronic disease populations and medication regimens, but its role during HCV treatment remains unknown. STUDY: Data from the prospective Virahep-C study were analyzed to examine relationships between SE and patient-driven deviations (ie, missed doses measured using electronic pill caps, and nonpersistence) from adherence to HCV antiviral treatment. SE was measured using the 17-item HCV Treatment Self-Efficacy scale. This measure provides a global estimate of a patient's confidence to undergo and adhere to HCV treatment, and can estimate SE in 4 underlying domains: communication SE (ie, confidence to communicate with health care provider), physical coping SE (ie, confidence to cope with physical side effects), psychological coping SE (ie, confidence to cope with psychiatric side effects), and treatment adherence SE (ie, confidence to take all medications as prescribed and attend doctor visits). Generalized estimating equations and Cox proportional hazards models were used to assess associations between SE and missed doses and nonpersistence, respectively. RESULTS: SE was associated with being in a relationship, educated, privately insured, and less depressed. Higher communication SE at TW24 reduced the risk of missed doses between TW24 and TW48. Higher baseline treatment adherence SE reduced the likelihood of nonpersistence between baseline and TW24. CONCLUSIONS: SE's relationship to HCV treatment adherence has promising clinical and research implications.
GOALS: To investigate the role of self-efficacy (SE) during hepatitis C virus (HCV) treatment. BACKGROUND: Adherence to chronic HCV treatment is critical. SE is an important predictor of medication adherence in a number of chronic disease populations and medication regimens, but its role during HCV treatment remains unknown. STUDY: Data from the prospective Virahep-C study were analyzed to examine relationships between SE and patient-driven deviations (ie, missed doses measured using electronic pill caps, and nonpersistence) from adherence to HCV antiviral treatment. SE was measured using the 17-item HCV Treatment Self-Efficacy scale. This measure provides a global estimate of a patient's confidence to undergo and adhere to HCV treatment, and can estimate SE in 4 underlying domains: communication SE (ie, confidence to communicate with health care provider), physical coping SE (ie, confidence to cope with physical side effects), psychological coping SE (ie, confidence to cope with psychiatric side effects), and treatment adherence SE (ie, confidence to take all medications as prescribed and attend doctor visits). Generalized estimating equations and Cox proportional hazards models were used to assess associations between SE and missed doses and nonpersistence, respectively. RESULTS: SE was associated with being in a relationship, educated, privately insured, and less depressed. Higher communication SE at TW24 reduced the risk of missed doses between TW24 and TW48. Higher baseline treatment adherence SE reduced the likelihood of nonpersistence between baseline and TW24. CONCLUSIONS: SE's relationship to HCV treatment adherence has promising clinical and research implications.
Authors: Terry R Barclay; Charles H Hinkin; Steven A Castellon; Karen I Mason; Matthew J Reinhard; Sarah D Marion; Andrew J Levine; Ramani S Durvasula Journal: Health Psychol Date: 2007-01 Impact factor: 4.267
Authors: Mallory O Johnson; Torsten B Neilands; Samantha E Dilworth; Stephen F Morin; Robert H Remien; Margaret A Chesney Journal: J Behav Med Date: 2007-06-23
Authors: Donna M Evon; Darmendra Ramcharran; Steven H Belle; Norah A Terrault; Robert J Fontana; Michael W Fried Journal: Am J Gastroenterol Date: 2009-09-29 Impact factor: 10.864
Authors: J J Weiss; L Bhatti; D T Dieterich; B R Edlin; D A Fishbein; M B Goetz; K Yu; G J Wagner Journal: Aliment Pharmacol Ther Date: 2008-08-01 Impact factor: 8.171
Authors: Vincent Lo Re; Valerianna K Amorosa; A Russell Localio; Rose O'Flynn; Valerie Teal; Zachariah Dorey-Stein; Jay R Kostman; Robert Gross Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079
Authors: Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong Journal: Value Health Date: 2008 Jan-Feb Impact factor: 5.725
Authors: Donna M Evon; Amit Verma; Karen A Dougherty; Betty Batey; Mark Russo; Steven Zacks; Roshan Shrestha; Michael W Fried Journal: Dig Dis Sci Date: 2007-03-30 Impact factor: 3.199
Authors: Gretchen Kimmick; Sara N Edmond; Hayden B Bosworth; Jeffrey Peppercorn; Paul K Marcom; Kimberly Blackwell; Francis J Keefe; Rebecca A Shelby Journal: Breast Date: 2015-07-16 Impact factor: 4.380
Authors: K D Cromwell; Y J Chiang; J Armer; P P Heppner; K Mungovan; M I Ross; J E Gershenwald; J E Lee; R E Royal; A Lucci; J N Cormier Journal: Eur J Cancer Care (Engl) Date: 2015-03-24 Impact factor: 2.520
Authors: Corrine I Voils; Heather A King; Carolyn T Thorpe; Dan V Blalock; Ian M Kronish; Bryce B Reeve; Colleen Boatright; Ziad F Gellad Journal: Dig Dis Sci Date: 2019-04-29 Impact factor: 3.487
Authors: Avy A Skolnik; Amanda Noska; Vera Yakovchenko; Jack Tsai; Natalie Jones; Allen L Gifford; D Keith McInnes Journal: BMC Health Serv Res Date: 2019-02-01 Impact factor: 2.655